Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • GSK India to sell...

    GSK India to sell Vemgal facility

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-02-08T09:30:13+05:30  |  Updated On 8 Feb 2020 9:30 AM IST
    GSK India to sell Vemgal facility

    As part of this strategic review, GSK India will explore future options for the Vemgal facility including a potential sale of the site, it added.

    New Delhi: Drug firm GlaxoSmithKline Pharmaceuticals recently reported a consolidated net loss of Rs 661.16 crore for the December 2019 quarter, mainly on account of financial impact related to the voluntary recall of Zinetac.

    The company had posted a net profit of Rs 113.67 crore for the corresponding period of the previous financial year, GlaxoSmithKline Pharmaceuticals said in a filing to the BSE.

    Following the recent decision to initiate a global voluntary recall of ranitidine products including Zinetac in India, the Ultimate Holding Company is continuing with investigations into the potential source of the NDMA and has initiated a comprehensive strategic review of the impact of this recall on all related assets in India, GlaxoSmithKline Pharmaceuticals said.

    As part of the ongoing strategic review, during the quarter, the holding company has recognised a financial impairment of Rs 640.31 crore connected to the under-utilisation of its manufacturing facilities and Rs 96.59 crore on account of other related assets/ cost, it added.

    Also, a charge of Rs 17 crore is recognised by Biddle Sawyer Ltd (subsidiary) on account of outstanding litigation matter, the company said.

    As part of this strategic review, GSK India will explore future options for the Vemgal facility including a potential sale of the site, it added.

    The company's consolidated revenue from operations stood at Rs 778.59 crore for the quarter under consideration. It was Rs 825.35 crore for the same period a year ago.

    "Our global innovation, performance and trust (IPT) strategy underpinned by our culture has guided investment of our resources in focus therapies which is continuing to show encouraging results with our promoted brands recording 11 per cent growth for the quarter," GlaxoSmithKline Pharmaceuticals Managing Director A Vaidheesh said.

    The results were impacted due to voluntary global recall of ranitidine products, including Zinetac, in India and trigger-based impairment charges primarily towards manufacturing facility at Vemgal, he added.

    Also Read: GSK, CEPI Collaborate To Develop Vaccine For 2019-NCoV Virus

    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok